Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.
08 February 2024 – 1 mins read
PARIS, FRANCE, 8 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023.
FY 2023 results presentation & highlights
Discover the key highlights and results presentation, showcasing Ipsen’s performance and dedication to delivering value to our stakeholders.
Investor and analyst conference call
An investor and analyst conference call, with presentations and an interactive Q&A session, took place after the FY 2023 results announcement.
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.
Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).
Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.
If you are experiencing difficulties registering for the investor and analyst conference call, please contact: nicolas.bogler@ipsen.com
Your dedicated contacts
Craig Marks
Vice President, Investor Relations
Nicolas Bogler
Senior Manager, Investor Relations
